Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620542 · ClinicalTrials.gov registry record · Phase 3
CRESTOR Athero Imaging Head to Head IVUS Study
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,333
- Enrollment target
NCT00620542 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,333 participants.
The verdict
NCT00620542, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,333 participants
- Enrollment target
Study Summary
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,333 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620542
The ClinicalTrials.gov registry entry for NCT00620542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00620542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620542 about?
NCT00620542 is a clinical study titled "CRESTOR Athero Imaging Head to Head IVUS Study". A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
What is the current status of trial NCT00620542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,333 participants. The study started on 2008-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00620542?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00620542?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.